Roland Buelow
Directeur Général chez TeneoOne, Inc.
Postes actifs de Roland Buelow
Sociétés | Poste | Début | Fin |
---|---|---|---|
TeneoOne, Inc.
TeneoOne, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., TeneoOne, Inc. develops innovative medicines. The CEO of the American company is Roland Buelow. | Directeur Général | - | - |
Ancora Biotech LLC
Ancora Biotech LLC BiotechnologyHealth Technology Ancora Biotech LLC is a privately held service provider that supports the clinical development of assets for TeneoTwo, TeneoFour, and TeneoTen, which are all part of TBIO, LLC. The company is based in Palo Alto, CA. Ancora oversees the manufacturing and clinical development of these assets, including TeneoTwo's clinical stage TNB-486, TeneoFour's preclinical TNB-738, and TeneoTen's development of preclinical anti-HBVxCD3 for the treatment of chronic hepatitis B. The company was founded by Roland Buelow. | Fondateur | - | - |
Président | - | - | |
Directeur Général | - | - | |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Directeur/Membre du Conseil | 06/12/2022 | - |
Historique de carrière de Roland Buelow
Anciens postes connus de Roland Buelow
Sociétés | Poste | Début | Fin |
---|---|---|---|
Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA. | Directeur/Membre du Conseil | 01/01/2007 | - |
Directeur Général | 06/04/2009 | 01/01/2015 | |
Fondateur | 23/03/2010 | 01/01/2015 | |
SangStat Medical Corp. | Directeur Technique/Scientifique/R&D | 01/01/2003 | 01/01/2003 |
TeneoBio, Inc.
TeneoBio, Inc. Miscellaneous Commercial ServicesCommercial Services TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA. | Directeur/Membre du Conseil | 11/08/2009 | - |
Directeur Général | 11/08/2009 | - | |
Fondateur | 11/08/2009 | - | |
THP Ltd
THP Ltd Engineering & ConstructionIndustrial Services Part of Graham Holdings Co., THP Ltd is a British company that provides structural and architectural engineering services. The company was founded by Roland Buelow. THP was acquired by Tribeca Learning Pty Ltd., part of Graham Holdings Co. from May 26, 2006 on March 29, 2001. | Fondateur | - | - |
Statistiques
Internationale
Etats-Unis | 7 |
Royaume-Uni | 2 |
Opérationnelle
Founder | 4 |
Chief Executive Officer | 4 |
Director/Board Member | 3 |
Sectorielle
Health Technology | 6 |
Industrial Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 7 |
---|---|
Open Monoclonal Technology, Inc.
Open Monoclonal Technology, Inc. BiotechnologyHealth Technology Open Monoclonal Technology, Inc. engages in the genetic engineering of animals for discovery of human therapeutic antibodies. The firm’s transgenic animal platforms include OmniRat, industry’s first human monoclonal antibody technology based on rats; OmniMouse, a transgenic mouse that complements OmniRat and expands epitope coverage and; OmniFlic, the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies. The company was founded in by Roland Buelow 2007 and is headquartered in San Diego, CA. | Health Technology |
SangStat Medical Corp. | Health Technology |
THP Ltd
THP Ltd Engineering & ConstructionIndustrial Services Part of Graham Holdings Co., THP Ltd is a British company that provides structural and architectural engineering services. The company was founded by Roland Buelow. THP was acquired by Tribeca Learning Pty Ltd., part of Graham Holdings Co. from May 26, 2006 on March 29, 2001. | Industrial Services |
TeneoBio, Inc.
TeneoBio, Inc. Miscellaneous Commercial ServicesCommercial Services TeneoBio, Inc. operates as a biotechnology company that develops biologics, human heavy chain antibodies, as therapeutics against cancer, autoimmunity, and infectious diseases. Its products provides treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. The company was founded by Roland Buelow, on August 9, 2009 and is headquartered in Menlo Park, CA. | Commercial Services |
TeneoOne, Inc.
TeneoOne, Inc. Pharmaceuticals: MajorHealth Technology Part of AbbVie, Inc., TeneoOne, Inc. develops innovative medicines. The CEO of the American company is Roland Buelow. | Health Technology |
Ancora Biotech LLC
Ancora Biotech LLC BiotechnologyHealth Technology Ancora Biotech LLC is a privately held service provider that supports the clinical development of assets for TeneoTwo, TeneoFour, and TeneoTen, which are all part of TBIO, LLC. The company is based in Palo Alto, CA. Ancora oversees the manufacturing and clinical development of these assets, including TeneoTwo's clinical stage TNB-486, TeneoFour's preclinical TNB-738, and TeneoTen's development of preclinical anti-HBVxCD3 for the treatment of chronic hepatitis B. The company was founded by Roland Buelow. | Health Technology |
Medikine, Inc.
Medikine, Inc. Pharmaceuticals: MajorHealth Technology Medikine, Inc. is a privately held biopharmaceutical company located in an undisclosed location. The American company's mission is to transform the discovery of oncology, autoimmune disorder, and infectious disease therapeutics by employing a versatile drug discovery platform that generates modular "peptikines." These peptikines are peptide mimetics of cytokines that are smaller in molecular size than, and structurally unrelated to, the natural cytokines they emulate. Medikine's lead candidate, mdk-703, is currently in a phase 1 clinical trial in healthy volunteers. Ronald W. Barrett has been the CEO of the company since 2016. | Health Technology |
- Bourse
- Insiders
- Roland Buelow
- Expérience